Hackensack Meridian Health
Trial Pipeline
Ceftriaxone for Post-Treatment Lyme Disease
NCT06785402
Fludarabine and Intermediate-dose TBI Followed by PTCy in Patients Undergoing Allo Transplant for Heme Malignancies
NCT07214688
Predictive Value of Lung Ultrasound for Respiratory Decompensation in Late Preterm Neonates
NCT07216053
Utility of 18F-rhPSMA-7.3 in the Diagnosis of Prostate Cancer After Focal Gland Treatment
NCT07011342
OBWELL: Innovative Psychotherapeutic Intervention to Treat Postpartum Depression
NCT06991166
Transitions of Care Clinic (TOCC)
NCT06937827
Neoadjuvant Lu-177-PSMA-617 in Patients With High Risk Localized Prostate Cancer Undergoing Radical Prostatectomy
NCT06798558
Leveraging the Emergency Department (LEAD) Study
NCT06605534
CanScan; Community-based Registry to Assess, Address and advaNce SCreening for cANcer Prevention and Management
NCT06804395
Endometrial Cell Collection With the PadKit
NCT06464107
Iscador® P (Mistletoe) Immunotherapy for Recurrent Osteogenic Sarcoma
NCT05726383
Support for Cancer Patients Awaiting News
NCT06199570
Evaluation of the Effects of Ketorolac Dose on Duration of Analgesia in Emergency Department (ED) Renal Colic Patients
NCT05776953
Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy
NCT05715229
Post Operative Urinary Retention (POUR) Following Thoracic Oncological Surgery
NCT05657990
Cardiac Rehabilitation of Stroke Survivors (SRP-CROSS)
NCT05651945
Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma
NCT05199311
ETMR One: An International Registry and Research Platform for Children With Embryonal Tumor With Multilayer Rosettes
NCT04794686
AMNIOX CORD Study - Radical Prostatectomy With and Without Cryopreserved Umbilical Cord Allograft
NCT04263025
Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma
NCT03909412
Post-operative Urinary Retention (POUR) Following Thoracic Surgery
NCT03609580
Respiratory Transition Without Continuous Positive Airway Pressure
NCT07390812
Dose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma
NCT02446236
A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
NCT01297764
Central Venous Access Study
NCT03480542
Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma
NCT01453101
Pediatric Head Lice Study Product Comparison
NCT02213055
Study Combining Bortezomib With High Dose Melphalan to Treat Multiple Myeloma
NCT00784823
Lived Experiences of Adolescents in the Treatment Process of Cancer and the Impact on Occupations
NCT00456209
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer
NCT00004906
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 9 |
| Phase 2 | 8 |
| Phase 4 | 1 |
What the Pipeline for Hackensack Meridian Health Shows
According to the ClinicalTrials.gov registry, Hackensack Meridian Health is linked to 57 US clinical trials across every stage of research activity. Of those, 48 studies are currently recruiting — about 84% of the sponsor's indexed portfolio — and 6 are already marked complete, representing roughly 11% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for Hackensack Meridian Health reports 1 late-stage studies (Phase 3 and Phase 4 combined) and 17 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for Hackensack Meridian Health is Multiple Myeloma with 5 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.